Program
elunetirom
Its studies are mostly in Bipolar Disorder · Depressive Disorder, Major, led by Autobahn Therapeutics.
Furthest: phase 2, since Sep 30, 20244 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Autobahn Therapeutics | 42 open or running | phase 2since Sep 30, 2024 | Aug 19, 2022 | none ahead |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2022First study: phase 1 study in MDDFirst studyNCT05528315 · 48 enrolled · Australia
- Sep 30, 2024Phase 2 study in Depressive Disorder, MajorNCT06633016 · 230 planned · United States
- Feb 18, 2025Phase 2 study in Bipolar DisorderNCT06869187 · 35 enrolled · United States
- May 29, 2026Phase 1 study in HealthyNCT07652697 · 18 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07652697Healthy · United States | 1 | Completed | Feb 17, 2025 | 18 |
| NCT06869187Bipolar Disorder · United States | 2 | Active, not recruiting | Apr 22, 2026 | 35 |
| NCT06633016Depressive Disorder, Major · United States | 2 | Recruiting | Jun 2026 | 230 |
| NCT05528315MDD · Australia | 1 | Completed | Jun 26, 2023 | 48 |
How it is read
Names in the registry
- “ABX-002”, 4 entries
Conditions, from the studies’ own filings
- Bipolar Disorder, 1 study
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.